Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 17/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782803 | 0.92 | KIT (0.95) | KITNPC1GAA | |
| SCHEMBL17782904 | 0.91 | KIT (0.72) | KIT | |
| SCHEMBL16365886 | 0.89 | KIT (1.00) | KITNPC1GAA | |
| SCHEMBL17782846 | 0.86 | KIT (0.81) | KITNPC1GAA | |
| SCHEMBL17782808 | 0.84 | KIT (0.81) | KIT | |
| SCHEMBL17782849 | 0.84 | KIT (0.59) | KIT | |
| SCHEMBL16365885 | 0.83 | KIT (0.95) | KITNPC1GAA | |
| SCHEMBL16365482 | 0.82 | KIT (0.82) | KIT | |
| SCHEMBL17782881 | 0.82 | KIT (1.00) | KITNPC1GAA | |
| SCHEMBL16365882 | 0.82 | KIT (0.82) | KITNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | claimed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3010906-B1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2019-06-12 | — | — | EP | disclosed |
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | AB SCIENCE (FR) | 2019-02-12 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202370-B2 | Benzimidazole derivatives as selective proteine kinase inhibitors | KIT, CHUK, CSNK1E | KIT 1/4885NPC1 3114/4885ABL1 121/4885 |
| US-20160152608-A1 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE PROTEINE KINASE INHIBITORS | KIT, CHUK, CSNK1E | KIT 1/4885NPC1 3114/4885ABL1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.